ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
61,206.17
-2.92%
S&P 500
5,217.96
0.07%
Dow Jones
39,448.24
0.15%
US Dollar vs Yen
155.8515
0.29%
Brent Oil
83.455
-0.59%
Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Kazia Therapeutics Ltd (KZIA)

  7. Kazia Therapeutics Ltd (KZIA) ニュース

KZIA

Kazia Therapeutics (KZIA)

Kazia Therapeutics Ltd
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:KZIA
日付受信時刻ニュースソース見出しコード企業名
2024/05/0121 : 45PR Newswire (US)KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTSNASDAQ:KZIAKazia Therapeutics Ltd
2024/03/2121 : 52PR Newswire (US)Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseasesNASDAQ:KZIAKazia Therapeutics Ltd
2024/03/1321 : 00PR Newswire (US)Kazia announces presentation of new data at AACR Annual MeetingNASDAQ:KZIAKazia Therapeutics Ltd
2024/02/2206 : 19Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KZIAKazia Therapeutics Ltd
2024/02/2123 : 19Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
2024/02/2121 : 30PR Newswire (US)Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary EndpointNASDAQ:KZIAKazia Therapeutics Ltd
2024/02/1505 : 41Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:KZIAKazia Therapeutics Ltd
2024/02/1308 : 35Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:KZIAKazia Therapeutics Ltd
2024/02/0614 : 15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:KZIAKazia Therapeutics Ltd
2024/02/0606 : 19Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KZIAKazia Therapeutics Ltd
2024/01/1906 : 30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
2024/01/1821 : 30PR Newswire (US)KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTSNASDAQ:KZIAKazia Therapeutics Ltd
2024/01/1306 : 05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
2023/12/2614 : 15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:KZIAKazia Therapeutics Ltd
2023/12/1607 : 26Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:KZIAKazia Therapeutics Ltd
2023/12/1606 : 49Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:KZIAKazia Therapeutics Ltd
2023/12/0622 : 31Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
2023/12/0608 : 02PR Newswire (US)Kazia Therapeutics Announces Closing of $2 Million Registered Direct OfferingNASDAQ:KZIAKazia Therapeutics Ltd
2023/12/0506 : 05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:KZIAKazia Therapeutics Ltd
2023/12/0122 : 30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
2023/12/0122 : 00PR Newswire (US)Kazia Therapeutics Announces $2 Million Registered Direct OfferingNASDAQ:KZIAKazia Therapeutics Ltd
2023/11/3006 : 19Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
2023/11/3006 : 02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
2023/11/2921 : 01PR Newswire (US)KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGYNASDAQ:KZIAKazia Therapeutics Ltd
2023/11/2121 : 30PR Newswire (US)KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETINGNASDAQ:KZIAKazia Therapeutics Ltd
2023/11/2106 : 39Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
2023/11/2106 : 30PR Newswire (US)KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATIONNASDAQ:KZIAKazia Therapeutics Ltd
2023/11/1523 : 13Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
2023/11/1522 : 30PR Newswire (US)KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETINGNASDAQ:KZIAKazia Therapeutics Ltd
2023/11/1021 : 01PR Newswire (US)KAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB PRECLINICAL DATA IN MELANOMANASDAQ:KZIAKazia Therapeutics Ltd
 Showing the most relevant articles for your search:NASDAQ:KZIA

最近閲覧した銘柄

USI
USTECH100
US Tech 100
CCOM
US30
US 30
CCOM
US100
US Tech 100
USOTC
BASFY
BASF (QX)
NYSE
XOM
Exxon Mobil
NYSE
MRK
Merck
NYSE
DIS
Walt Disney
AMEX
XLF
Financial Select Sector
AMEX
SPY
SPDR S&P 500
NASDAQ
NVDA
NVIDIA
USOTC
ADDYY
Adidas (QX)
FX
USDJPY
US Dollar vs Yen
FX
USDGBP
US Dollar vs Sterling
NASDAQ
TSLA
Tesla
COIN
BTCUSD
Bitcoin
NYSE
BAC
Bank of America
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有